Cargando…
In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates
In this study, we investigated the in vitro activity and resistance mechanisms of the new generation tetracycline agents, namely eravacycline, omadacycline, and tigecycline, against Staphylococcus aureus isolates. A total of 1,017 non-duplicate S. aureus isolates were collected and subjected to susc...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722764/ https://www.ncbi.nlm.nih.gov/pubmed/36483205 http://dx.doi.org/10.3389/fmicb.2022.1043736 |
_version_ | 1784844027727708160 |
---|---|
author | Zeng, Weiliang Zhang, Xiaotuan Liu, Yan Zhang, Yi Xu, Mengxin Wang, Sipei Sun, Yao Zhou, Tieli Chen, Lijiang |
author_facet | Zeng, Weiliang Zhang, Xiaotuan Liu, Yan Zhang, Yi Xu, Mengxin Wang, Sipei Sun, Yao Zhou, Tieli Chen, Lijiang |
author_sort | Zeng, Weiliang |
collection | PubMed |
description | In this study, we investigated the in vitro activity and resistance mechanisms of the new generation tetracycline agents, namely eravacycline, omadacycline, and tigecycline, against Staphylococcus aureus isolates. A total of 1,017 non-duplicate S. aureus isolates were collected and subjected to susceptibility testing against eravacycline, omadacycline, and tigecycline using the broth microdilution method. Tetracyclines-resistant (eravacycline/omadacycline/tigecycline-resistant) isolates were selected to elucidate the resistance mechanisms using polymerase chain reaction (PCR), cloning experiment, efflux pump inhibition, and quantitative real-time PCR. The results of the antibacterial susceptibility testing showed that compared with omadacycline, eravacycline and tigecycline had superior antibacterial activity against S. aureus isolates. Among 1,017 S. aureus, 41 tetracyclines-resistant isolates were identified. These resistant isolates possessed at least one tetracycline resistance gene and genetic mutation in the MepRAB efflux pump and 30S ribosome units. A frameshift mutation in mepB was detected in most tetracyclines-resistant strains (except for JP3349) compared with tetracyclines-susceptible (eravacycline/omadacycline/tigecycline-susceptible) strains. This was first shown to decrease susceptibility to omadacycline, but not to eravacycline and tigecycline. After treatment with eravacycline, omadacycline or tigecycline, overexpression of mepA, tet38, tet(K) and tet(L) was detected. Moreover, multi-locus sequence typing showed a major clonal dissemination type, ST5, and its variant ST764 were seen in most tetracyclines-resistant strains. To conclude, eravacycline and tigecycline exhibited better activity against S. aureus including tetracycline-resistant isolates than omadacycline. The resistance to these new generation tetracyclines due to an accumulation of many resistance mechanisms. |
format | Online Article Text |
id | pubmed-9722764 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-97227642022-12-07 In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates Zeng, Weiliang Zhang, Xiaotuan Liu, Yan Zhang, Yi Xu, Mengxin Wang, Sipei Sun, Yao Zhou, Tieli Chen, Lijiang Front Microbiol Microbiology In this study, we investigated the in vitro activity and resistance mechanisms of the new generation tetracycline agents, namely eravacycline, omadacycline, and tigecycline, against Staphylococcus aureus isolates. A total of 1,017 non-duplicate S. aureus isolates were collected and subjected to susceptibility testing against eravacycline, omadacycline, and tigecycline using the broth microdilution method. Tetracyclines-resistant (eravacycline/omadacycline/tigecycline-resistant) isolates were selected to elucidate the resistance mechanisms using polymerase chain reaction (PCR), cloning experiment, efflux pump inhibition, and quantitative real-time PCR. The results of the antibacterial susceptibility testing showed that compared with omadacycline, eravacycline and tigecycline had superior antibacterial activity against S. aureus isolates. Among 1,017 S. aureus, 41 tetracyclines-resistant isolates were identified. These resistant isolates possessed at least one tetracycline resistance gene and genetic mutation in the MepRAB efflux pump and 30S ribosome units. A frameshift mutation in mepB was detected in most tetracyclines-resistant strains (except for JP3349) compared with tetracyclines-susceptible (eravacycline/omadacycline/tigecycline-susceptible) strains. This was first shown to decrease susceptibility to omadacycline, but not to eravacycline and tigecycline. After treatment with eravacycline, omadacycline or tigecycline, overexpression of mepA, tet38, tet(K) and tet(L) was detected. Moreover, multi-locus sequence typing showed a major clonal dissemination type, ST5, and its variant ST764 were seen in most tetracyclines-resistant strains. To conclude, eravacycline and tigecycline exhibited better activity against S. aureus including tetracycline-resistant isolates than omadacycline. The resistance to these new generation tetracyclines due to an accumulation of many resistance mechanisms. Frontiers Media S.A. 2022-11-22 /pmc/articles/PMC9722764/ /pubmed/36483205 http://dx.doi.org/10.3389/fmicb.2022.1043736 Text en Copyright © 2022 Zeng, Zhang, Liu, Zhang, Xu, Wang, Sun, Zhou and Chen. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Microbiology Zeng, Weiliang Zhang, Xiaotuan Liu, Yan Zhang, Yi Xu, Mengxin Wang, Sipei Sun, Yao Zhou, Tieli Chen, Lijiang In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates |
title | In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates |
title_full | In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates |
title_fullStr | In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates |
title_full_unstemmed | In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates |
title_short | In vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical Staphylococcus aureus isolates |
title_sort | in vitro antimicrobial activity and resistance mechanisms of the new generation tetracycline agents, eravacycline, omadacycline, and tigecycline against clinical staphylococcus aureus isolates |
topic | Microbiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9722764/ https://www.ncbi.nlm.nih.gov/pubmed/36483205 http://dx.doi.org/10.3389/fmicb.2022.1043736 |
work_keys_str_mv | AT zengweiliang invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates AT zhangxiaotuan invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates AT liuyan invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates AT zhangyi invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates AT xumengxin invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates AT wangsipei invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates AT sunyao invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates AT zhoutieli invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates AT chenlijiang invitroantimicrobialactivityandresistancemechanismsofthenewgenerationtetracyclineagentseravacyclineomadacyclineandtigecyclineagainstclinicalstaphylococcusaureusisolates |